Listen to this article Gaithersburg-based Novavax Inc. Tuesday announced its Nuvaxovid XBB.1.5 COVID-19 vaccine (NVX-CoV2601) ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The emergency use listing is based on non-clinical data where the vaccine demonstrated immune responses against variants in ...

Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in ...

Novavax's updated COVID-19 vaccine is the only updated protein-based non-mRNA COVID-19 vaccine available in the European Union for individuals aged 12 and older Novavax is working closely with EU ...

The single-target vaccine is aimed at the XBB.1.5 Omicron subvariant of the coronavirus, which was dominant in the U.S. for ...

The U.S Food and Drug Administration approved the first chikungunya vaccine- Ixchiq Ixchiq is administered as a single dose intra-muscularly for individuals over 18 years of age and older who are ...

A: The CDC has authorized two RSV vaccines for the prevention of lower respiratory tract disease in people 60 and older. The ...

University of Wisconsin School of Medicine and Public Health researchers are studying how a booster COVID-19 vaccine works ...

Novavax announced that Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the ...